Updated Jul 17, 2026
Upgrade to a paid plan to see AI rating history on the chart.
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest su…
DIVO has raised its monthly payout three years running and sits on $5.25 billion in assets, but one holding carries a debt load that raises questions about how…
Management is promising structural growth without shipping more drives, and the market is buying it. But the real test of that high-tech promise is around the…
Zenas BioPharma (ZBIO) remains undervalued, as investor concerns over its phase 3 INDIGO trial for o
Management laid out a bigger vision for the business, and investors have more than agreed. The question now is how much of that future is already in the price.
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.
It’s the first pill that lowers blood cholesterol far better than statins, medicines that a quarter of adults take to reduce their risk of heart attack and str…
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next…
Not investment advice. Past performance does not guarantee future results. Full disclaimer